Alethio Therapeutics
alethiotherapeutics.com ↗ · Abingdon-on-Thames, United Kingdom · €80.46 million
via eu-startups.com · Nov 7A biotech company developing targeted monoclonal antibody therapies (e.g., ATX-011) for myeloproliferative neoplasms such as essential thrombocythaemia.
bottleneck › Scaling pre‑clinical and clinical manufacturing pipelines for biologics while integrating complex discovery data.
contact
✉ hello@alethiotx.com generalsource
We can build a Next.js dashboard that lets your scientists query experimental results with semantic vector search, cutting data‑retrieval time from days to seconds. This will free up your R&D team to focus on assay design and patient outcomes rather than hunting through spreadsheets.
email draft › hello@alethiotx.com
intent: build with them (no hiring signal or clear bottleneck, so propose a partnership)
Alethio Therapeutics: a thought on Scaling pre‑clinical and clinical manufacturing pipelines fo
Hi Adam, Congrats on the new funding (https://www.eu-startups.com/2026/11/oxford-spin-out-alethio-therapeutics-raises-e80-46-million-series-a-to-advance-targeted-blood-cancer-therapies/). I came across Alethio Therapeutics: A biotech company developing targeted monoclonal antibody therapies (e.g. I'd like to build something with you. One place we could start: scaling pre‑clinical and clinical manufacturing pipelines for biologics while integrating complex discovery data. Open to a quick call to see if there is a fit? If this isn't relevant, just reply "no" and I won't follow up.address published on this page ↗
site built with
- WordPress
signals
- funding rss · Nov 6
qualification
- fit10000%
- reach10000%
- evidence8500%
timeline
similar companies
- why now › Newly found at series a stage
- why now › Raised money
score › fit 25/25 · identity 12/15 · people 20/20 · connections 15/20 · contact 20/20
missing › tech stack
people
- Adam Mead · Co‑founder
“Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
- Beth Psaila · Co‑founder
“Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
- Rohit Batta · Chief Executive Officer in
“Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”
connections
- Adam Mead founded Alethio Therapeutics
“Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
- Beth Psaila cofounded Alethio Therapeutics
“Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
- Rohit Batta works at Alethio Therapeutics
“Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”
- Graziano Seghezzi invested in Alethio Therapeutics
“The round was co‑led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises”
- Maxwell DeNies invested in Alethio Therapeutics
“The round was co‑led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises”
- Sally Dewhurst backed by Alethio Therapeutics
“Sally Dewhurst , Principal at Oxford Science Enterprises”